| William
C. Mills III, Partner, Advent
International, Mr. Mills has over 21 years of venture capital experience, and focuses on investments in the biotechnology, emerging pharmaceutical and medical technology sectors. He is currently a Director of Ardais Corporation (Lead Director), Enanta Pharmaceuticals Inc. and Stereotaxis, Inc., and is a member of the Research and Technology Development Committee and Equity Subcommittee of Beth Israel Deaconess Medical Center (Harvard). Before joining Advent, Mr. Mills spent eleven years with The Venture Capital Fund of New England as a General Partner. His specific area of responsibility was the partnership's pharmaceutical, biotechnology and medical device portfolio. Prior to that, he spent seven years at PaineWebber Ventures/Ampersand Ventures in Boston, where as a Managing General Partner he concentrated on early stage technology and biotechnology investments for a series of partnerships affiliated with PaineWebber. Mr. Mills received an A.B. in Chemistry, cum laude, from Princeton University, an S.M. in Chemistry from the Massachusetts Institute of Technology (organometallic photochemistry) and an M.S. in Management from MIT's Sloan School of Management. |
 |
| Jean M. George, Partner, Advanced Technology Ventures Jean George joined Advanced Technology Ventures as a Partner in 2002, with 20 years of experience in the biopharmaceutical industry, including 10 years at Genzyme Corporation. Jean assesses new deals in the life sciences and therapeutics markets, and utlizes her operational skills to actively assist portfolio companies on their strategic planning and development. Jean is currently on the Boards of NuGenesis Technologies Corp. and Microbia, Inc. Prior to joining ATV, Jean was a Director at BancBoston Ventures, where she led the health care team’s investment activity in NuGenesis Technologies Corp., Microbia, Inc., Syntonix Pharmaceuticals and Neurometrix, Inc. Previously, during Jean’s tenure at Genzyme, she held a variety of operational roles in marketing, product development and business development, including Vice President of Global Sales and Marketing. Jean was a member of the founding team of the Genzyme Tissue Repair Division, and held responsibilities for identifying new product opportunities and potential acquisition candidates for the Therapeutic Products Division. In addition to her extensive operating background, Jean spent six years working in chemistry and bioresearch fields. Jean earned an MBA from Simmons College Graduate School of Management and a BS in Biology from the University of Maine. |
 |
| Margaret
A. Flanagan, Ph.D., Global Alliance
Director, Enabling
Prior to joining AstraZeneca in January 2001, Dr. Flanagan was the Senior Director, Business Development at Hybridon, Inc., Cambridge, MA (1997-2000), President, BioAlliance, Inc., Lexington, MA (1997-1999), Associate Director and Director, Licensing and Proprietary Drug Discovery, Oncogene Science Inc., Cambridge, MA (1994-1996), and Senior Scientist II, Merrell Dow Pharmaceuticals (now Aventis), Cincinnati, OH (1985-1994). Dr. Flanagan did her post-doctoral training in the Laboratory of Chemical Biology, NIADDK, National Institutes of Health, after receiving her Ph.D. degree in Physical Chemistry from Indiana University, Bloomington in 1983. Dr. Flanagan received a B.S. in Chemistry from the University of Kansas in 1977. |
 |
| Jean-François Formela, Senior Principal, Atlas Venture Jean-François Formela joined Atlas Venture in 1993. Previously, he was Senior Director, Medical Marketing and Scientific Affairs at Schering-Plough in the US. During his tenure there, he was responsible for the marketing of Intron A, Schering-Plough's alpha-interferon. In his last position at Schering-Plough, he directed the US Phase IV studies in all therapeutic areas, as well as the health economics, medical information, and biotechnology pre-marketing groups. As a medical doctor, Jean-François practiced emergency medicine at Necker University hospital in Paris. Since joining Atlas Venture, Jean-François
has been involved in the formation of companies such as ArQule (Nasdaq:
ARQL), MorphoSys (Neuer Markt: MORG), Exelixis (Nasdaq: EXEL), deCODE
genetics (Nasdaq: DCGN), Variagenics (Nasdaq: VGNX), Structural
GenomiX, CellZome, Archemix and Akceli. Board participation includes: |
 |
| Prof. Dr. Jesper Zeuthen, Managing Director, BankInvest Bio Venture Jesper Zeuthen has been working for the BankInvest Group as a consultant since 1988, and he decided to join us full time in spring 2000 working primarily with venture capital. Previously, Jesper Zeuthen has worked as Head of R & D at Novo Nordisk and Head of Research at The Danish Cancer Society. He is the author of more than 200 publications in immunology, cell biology and molecular biology and served as adjunct professor of biotechnology at the University of Copenhagen. |
 |
| Dr.
Kalevi Kurkijärvi Ph.D., Senior
Partner, Chairman & CEO, Dr. Kurkijärvi is founder,senior partner of Bio Fund Management Oy Ltd and has been chairman & CEO since the founding of the company. He also acts as chairman & CEO in his family company, Biketex Oy. In addition to his service on the board of directors, funding work, and investor relations, he serves in managing investment targets, especially, in the pharmaceuticals industry. He is serving or has served as a chairman of the board of directors at BioTie Therapies Oy, MAP Medical Oy, Bio Orbit Oy, Abmin Technologies Oy, FibroGen Europe Oy, Pribori Oy, Hormos Medical Oy, Hormos Medical Oy and Rados Technology Oy. Additionally, he is and has been on boards of directors of more than 20 international life sciences companies among others: Ark Therapeutics Ltd (UK), FibroGen Inc. (USA), Paratek Pharmaceuticals Inc. (USA), A+ Science Invest AB (Sweden), HyTest Oy, Aboa Tech Oy and Juvantia Pharma Ltd. Prior to founding of BioFund, Dr. Kurkijärvi was director of venture capital group in the Finnish National Fund of Research and Development Sitra. He has also served as executive vice president at Wallac Oy and as president and CEO at Pharmacia Diagnostics Production Oy. He also worked for several years as a researcher and teacher at the University of Turku, publishing several scientific papers during that time. Dr. Kurkijärvi has a PhD degree in biochemistry and molecular biology and completed during 1988-1989 The Management and Business Adminstration Program at Turku School of Economics. |
 |
| G. Steven Burrill, CEO, Burrill & Company G. Steven Burrill has been very involved in the growth and prosperity of the biotechnology industry for more than 35 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained promoters. Mr. Burrill currently serves as Board Chairman for AniGenics and Paradigm Genetics (NASDAQ: PDGM) and as a Board member of AgraQuest, Crosscart, DepoMed (AMEX: DMI), MetriGenix, Sulis Pharmaceuticals, Targacept, Transgene (NASDAQ: TRGNY), Third Wave Technologies (NASDAQ: TWTI) and ValiGen. He created, and continues to host, some of the industry’s most important meetings, and he authors the seminal annual report on the biotechnology industry – considered by many to be the "bible" of the industry. He is a frequent writer and speaker worldwide, explaining, promoting and helping to guide this industry. Steve Burrill’s visibility is hard evidence of his long-term focus on helping build one of the world’s premier industries. Mr. Burrill has authored a variety of articles and books about the life sciences, encompassing business, management and financial concerns of these companies. He also is a regular columnist for BioPharm, and American Genomics and Proteomics Technology. Mr. Burrill has authored annual reports on the U.S. and European biotechnology industry for the last 15 years. Biotech 2001: Life Sciences-Genomics, Proteomics...and More is Mr. Burrill's most recent publication. |
| Pierre Cantin, Partner, CDP Capital Technology Ventures Pierre Cantin joined CDP Capital – Technology Ventures in 2001 and currently holds the position of Partner, focusing primarily on mergers and acquisitions. He has nearly 20 years of experience, primarily in finance, including seven years in the life sciences sector. Before joining CDP Capital – Technology Ventures, he held the position of Senior Vice-President and Director of KPMG Corporate Finance, where he took part in several mergers and acquisitions, company sales, private placements, strategic alliances and business valuations. More specifically, he acted as the principal financial advisor in several acquisitions, including Technilab Pharma (acquired by Merckle GmbH) and Draxis Health (TSE: DAX), as well as in a number of divestitures. Prior to that, he occupied various commercial and management positions with the Royal Bank of Canada, including three years as head of the Montreal Life Sciences Group during which time he put in place new financing for several companies in this sector. Mr. Cantin holds a Master of Business Administration, with a major in Finance, from the École des Hautes Études Commerciales and a Bachelor of Education, with a major in Exercise Physiology, from McGill University. He is also a graduate of the Canadian Securities Institute. |
 |
| P. Louis Myers Ph.D, J.D, Principal, Fish & Richardson P.C. Louis Myers, Ph.D., is a principal of the national law firm of Fish & Richardson P.C. Dr. Myers counsels life sciences clients on the formation and execution of intellectual property strategies, usually in the context of over all business planning and management including product development, technological issues, competitive and collaborative relationships, financing strategies, and the acquisition of technology, and other business considerations. This can include patent drafting and prosecution; the provision of infringement, validity, freedom-to-operate, and patent landscape opinions; due diligence investigations; and drafting and analyzing IP-related licenses and other agreements. Dr. Myers has worked in most of the technologies and fields important to life sciences companies, including basic molecular biology, geno/prote/pheno/chemo/glycomics, bioinformatics, chip-array technologies, small molecule/organic chemistry, drug discovery, gene and cell-based therapies, immunology, antibody-based therapies and diagnosis, transgenic animals and plants, DNA sequence analysis, nucleic acid detection and amplification systems, the use of lasers in medicine and surgery, and medical and biochemical instrumentation and devices. Dr. Myers earned his Ph.D. in Biology from Harvard University, where he also did his Postdoctoral work. He earned his law degree from Harvard Law School. He has taught Patent Law at Suffolk University Law School. |
 |
| Jan
van Heek, Executive Vice President, Therapeutics
and Genetics, Jan van Heek joined Genzyme in 1991. |
 |
| Dr.
Jeffrey S. Flier, Chief Academic Officer,
Harvard Faculty Dean Jeffrey S. Flier is currently the George C. Reisman
Professor of Medicine at Harvard Medical School, and Chief Academic
Officer and Harvard Faculty Dean for Academic Affairs at Beth Israel
Deaconess Medical Center. Dr. Flier trained in Internal Medicine at the Mount Sinai Hospital (1972-74), following which he took a position as a Clinical Associate at the National Institutes of Health training in clinical endocrinology and basic research in the area of receptor biology. His accomplishments include the discovery that autoantibodies to the insulin receptor were a cause of insulin resistant diabetes in man. These antibodies played a critical role in his subsequent investigations of the biology of insulin receptors in normal and disease states. In 1978, Dr. Flier joined the faculty of Medicine at Harvard Medical School, where he served as Chief of the Diabetes Unit at Beth Israel Hospital. He has remained at Harvard and Beth Israel where he became the George C. Reisman Professor of Medicine (1998), Vice Chair for Research of the Department of Medicine (1998-2002), Chief of the Division of Endocrinology (1990-2001) and Chief Academic Officer (2002-). While Chief of the Division of Endocrinology, Dr. Flier built the division into a position of prominence in the field; the division supports the research of 40 scientists with over $5,000,000 in direct research grants. Dr. Flier's research has produced major insights into the molecular mechanism of insulin action, the molecular mechanisms of insulin resistance in human disease, and the molecular pathophysiology of obesity. He has authored more than 200 scholarly papers and reviews, and is a leading international authority in these areas. Most recently, his group has assumed a leading position in the use of transgenic models to explore the pathophysiology of metabolic disease, and in studies of the biological role and mechanism of action of the fat-derived hormone leptin. Dr. Flier has received a number of honors and awards including election to the American Society for Clinical Investigation, the Association of American Physicians, and past President of the Interurban Clinical Club. He has had numerous visiting professorships in Departments of Medicine in the United States, and was awarded an Honorary Doctorate in Medicine by the University of Athens in 1997. Most recently, he was elected into membership in the American Academy of Arts and Sciences (2001). Dr. Flier is married to Dr. Eleftheria Maratos-Flier, M.D., who is also on the faculty of Harvard Medical School. The Fliers have collaborated on research in the area of neuroendocrine control of body weight over the past several years. They have two daughters, Lydia age 13, and Sarah age 24, and live in Newton, Mass. |
 |
| Dr. Gary T. Shearman, Investment Advisor, HBM Partners AG Dr. Shearman has been a senior pharmaceutical executive with extensive global research and drug development leadership experience in multiple therapeutic areas including gene therapy. He has been responsible for creating and implementing global drug development and regulatory strategies resulting in over twenty regulatory submissions and product approvals on a worldwide basis in major markets such as the United States, the European Union and Japan. He reengineered global drug development operations achieving highly competitive drug development times and quality and he managed diverse research and drug development functions located in various countries. From 1998 until 2000, Dr. Shearman was Deputy Head of Global Research and Drug Development and Senior Vice President of Global Drug Development at Rhône-Poulenc Rorer (RPR). He was responsible for ensuring the global implementation of the corporate product strategy and coordinated all R&D, marketing and manufacturing activities related to two blockbuster oncology and cardiovascular drugs. From 1994 until 1998, Dr. Shearman was Senior Vice President of Pharmaceutical Drug Development for Rhône-Poulenc Rorer. He coordinated global drug development and regulatory strategies and directed departments with a consolidated annual budget of approximately $450 million. In 1992, Dr. Shearman joined RPR as Vice President of Worldwide Regulatory Affairs. Before joining RPR, Dr. Shearman was a Regulatory Affairs Director (1989–1992) and Associate Director Clinical Neurosciences (1987–1988) for Merck & Co. From 1983 until 1987 he worked for Sandoz in drug discovery and as a Project Leader for central nervous system (CNS) products. Dr. Shearman received a Ph.D. in Pharmaceutical Sciences and an MS in Pharmacology and Toxicology from the University of Rhode Island and a BA in Psychology from the University of Massachusetts. He is a member of the R & D advisory board for the Center Medicines Research Institute and Tufts Center for the Study of Drug Development. |
 |
| Christopher K. Mirabelli Ph.D, General Partner, HealthCare Ventures, LLC Dr. Mirabelli has over twenty years of experience in the pharmaceutical and biotechnology industry and in biomedical research as both a senior executive and scientist. Dr. Mirabelli has been a General Partner at HealthCare Ventures, LLC (HCV) since 2000. HCV, founded in 1985, is a leading venture capital group focused on investing in and building significant companies in the biopharmaceutical industry. HCV has raised over $1 Billion in seven funds and has been a leading investor in companies such as Human Genome Sciences, MedImmune, Shire Pharmaceuticals, and LeukoSite. Dr. Mirabelli serves as Chairman of the Board of Directors of TolerRx, Inc., Thios Pharmaceuticals, Inc., and CellGate, Inc. and as a member of the Board of Directors of ActivBiotics, Inc., Critical Therapeutics, Inc., Xanthus Life Sciences, Inc., and Replidyne, Inc. Prior to joining HealthCare Ventures, Dr. Mirabelli served as Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999. Under his leadership, LeukoSite became a premier company in the discovery and development of therapeutics targeting white blood cell-mediated diseases, raised over $125MM in capital in private, corporate and public financings, established corporate R&D alliances with major pharmaceutical companies, and through internal R&D and the acquisition of technology and other companies constructed a pipeline of multiple product opportunities spanning late phase clinical development and early research and drug discovery. LeukoSite’s success culminated in its merger with Millennium Pharmaceuticals in December, 1999. Under Dr. Mirabelli’s direction, LeukoSite grew from a valuation of $16MM at inception to near $1 Billion upon completion of the merger. Dr. Mirabelli presided over the integration of LeukoSite into Millennium as President of Pharmaceutical R&D and a member of the Company’s Board of Directors until mid-2000. Dr. Mirabelli was a founder of Isis Pharmaceuticals, Inc., where he served as Executive Vice President from 1992 to 1993, Senior Vice President of Research and Preclinical Development from 1991 to 1992, and Vice President of Research from 1989 to 1991. He was a member of SmithKline and French Laboratories R&D Division from 1981 to 1988 where he held a number of positions including director of the department of Molecular Pharmacology. Dr. Mirabelli received his Ph.D. degree in molecular pharmacology from Baylor College of Medicine in Houston, Texas in 1981. He has authored 192 scientific publications, abstracts and review articles and is an author on 24 issued patents. |
 |
| Stan Yakatan, Chairman, Katan Associates After 30 years as a successful CEO, entrepreneur,and operational manager, Stan Yakatan has dedicated the last 7 years of his career to sharing his experiences with management teams interested in building technology based companies. His experience as an executive and in several instances serving as CEO with New England Nuclear, EI Dupont, ICN Pharma, New Brunswick Scientific and Biosearch, provided him with management and corporate finance acumen that he enjoys sharing with others. He has founded or co-founded in excess of 15 companies in the United States, Canada, Israel, France and Germany and in many cases served as the initial CEO, and Chairman of these companies. He currently sits on the board of directors of several public and private companies and has advised several of the world's leading venture capital firms including TVM (Germany), Ventana (USA), MSP (USA) and Biocapital (Canada). He has completed and advised on numerous acquisitions and corporate finance transactions raising in excess of $1.0 billion dollars in the public and private capital financing markets. He is a frequent speaker at financial and biotechnology conferences throughout the world speaking on topics including, "Capital Raising for the Technology-Based Start-Up" and "The Need to be Global in the Quest for Capital and Partners". Rick Biondi, Editor of Lab Business Magazine stated," Mr Yakatan is a venture capital raising Guru and it is part of his genetic make up." He currently serves as the strategic advisor to the state government of Victoria, Australia and is the Chairman of Katan Associates International with headquarters in New York City. |
 |
| Eileen
Smith Ewing, Esq., Eileen Smith Ewing represents biotechnology and
high-technology clients in intellectual property licensing and technology
transfers. In addition to a complex transactional practice, she
provides ongoing counsel to corporations, partnerships, and limited
liability companies on a wide range of legal matters. Ms. Ewing
also provides her private and public companies in domestic and transnational
mergers, acquisitions, joint ventures, and other strategic corporate
alliances. She has experience in counseling issuers, underwriters,
and venture capital funds with respect to public offerings and private
placements of securities. |
 |
| Dr. Ian Nisbet, VELCADE Product Leader, Millennium Pharmaceuticals Inc Ian Nisbet, Ph.D. works at Millennium Pharmaceuticals, Inc. (MPI) where he is Product Leader for VELCADE, a new oncology drug that is expected to receive marketing approval from the FDA this year. Ian originally joined Millennium BioTherapeutics (MBio) [a subsidiary of MPI] as Program Director for the Therapeutic Antibody Program in February 1998. When MBio was merged into MPI in December 1999, Ian moved into the position of Senior Director, Licensing and M&A in Millennium’s Corporate Development group. In this role, Ian supported Millennium’s extremely aggressive growth objectives through the development and implementation of strategic M&A and licensing initiatives. During 2001, Ian was a key member of the team that successfully negotiated Millennium’s first two in-licensed clinical products. In the same year, Ian led the diligence team for Millennium’s acquisition of COR Therapeutics and then went on to lead the merger integration team and become the initial site manager for Millennium San Francisco (the ex-COR site). Upon returning to Boston in mid-2002, Ian moved into his current position. Before joining Millennium, Ian worked for the Australian pharmaceutical company CSL Limited in a career spanning more than 17 years. At CSL Ian held a number of different scientific and management positions, the last being Director, Planning and Coordination. In that position Ian was responsible for the development and implementation of project management at CSL, together with overall management of CSL’s project management system and direct management of a number of CSL’s external relationships. Ian received his B.Sc. in microbiology and biochemistry from the University of Melbourne and his Ph.D. in molecular biology from Monash University. He is also a graduate of the Advanced Management Program from the Melbourne Business School at the University of Melbourne. |
 |
| Andrew Greene, Managing Director, Merlin Biosciences Andrew Greene is a member of Merlin's Investment Committee and Board of Directors. He is a Director of portfolio companies of the Merlin Fund L.P. and the Merlin Biosciences Fund L.P. Mr. Greene joined Merlin from Merrill Lynch International, where he was Director of Healthcare Investment Banking. He ran the Healthcare Investment Banking team at HSBC Investment Bank. His team advised biotechnology companies in Europe on fundraising and mergers and acquisitions. He also worked for the international management consulting firms Booz, Allen & Hamilton, Inc. and Cap Gemini Sogeti, where he advised major private equity groups on healthcare acquisitions and leveraged buyouts, and also advised hospital, drug, medical device, and insurance companies on corporate strategy. Mr Greene worked in Corporate Treasury for Lifemark Corporation and was involved in the sale of Lifemark to American Medical International (now Tenet Healthcare). His first medical work was on a $10 million NIH grant at Harvard Medical School / Massachusetts General Hospital. He has an MBA / Masters of Accounting degree from Rice University and a BA from Cornell University. |
| Dr.
Samir Master, Vice President, Business
Development and Biography to follow shortly |
 |
| Michael Lytton, General Partner, Oxford BioScience Partners Michael Lytton is a General Partner of Oxford Bioscience Partners. Prior to that, he was Partner, Chairman of the Technology Group and a member of the Executive Committee of Palmer & Dodge LLP, a Boston-based law firm. Mr. Lytton serves on the Boards of Directors of Acambis plc, ActivX Biosciences Inc., Descartes Therapeutics, Inc, GPC Biotech AG, Graffinity Pharmaceuticals AG, Psychiatric Genomics Inc, and Rib-X Pharmaceuticals, Inc. Mr. Lytton is a member of the Research and Technology Development Committee of the Beth Israel Deaconess Medical Center (an affiliated Harvard teaching hospital). Mr. Lytton is a member of the Board of Overseers and the Research and Technology Committee of the Center for Blood Research, Harvard Medical School. Mr. Lytton is also a member of the Translational Research Subcommittee of the Brigham and Women’s Hospital (a Harvard hospital). Mr. Lytton also serves as a member of the Biotech Advisory Committee to Connecticut Innovations, a quasi-public seed venture fund for Connecticut-based start-up biomedical companies. Mr. Lytton writes a column on issues facing early-stage biomedical companies for Start-Up magazine, published by Windhover Information. Mr. Lytton has served on the Executive Board of the MIT Enterprise Forum and the Patent Committee of the Boston University Medical Center. Mr. Lytton was a summa cum laude graduate of Princeton University and a recipient of a Fulbright Scholarship for study at the University of London. Mr. Lytton received a J.D. degree cum laude from Harvard Law School. Mr. Lytton also received a M.Sc. degree in Epidemiology and Medical Statistics from the London School of Hygiene and Tropical Medicine. |
 |
| Dr. Christoph H. Westphal, General Partner, Polaris Venture Partners Christoph H. Westphal is a general partner in our Boston office. Christoph joined Polaris in June 2000. He focuses on investment opportunities in medical technology and material science. Experience: Prior to joining Polaris, Christoph was at McKinsey & Co. in Boston and Los Angeles, working with high-growth biotech, pharmaceutical, materials science, wireless, and e-commerce companies. He was lead author on several papers published in Cell and Nature Genetics and is the inventor on two patents in the areas of cancer genetics and metabolic diseases. Boards: Christoph represents or has represented Polaris on the boards of directors of Advion BioSciences, Athenix Corp, Saegis Pharmaceuticals, eNOS Pharmaceuticals, Hydra BioSciences, and Nanosys. He was also founder and start-up CEO, and serves as vice chairman of both Momenta Pharmaceuticals, Inc. and Alnylam Pharmaceuticals. Education: Christoph completed his MD at Harvard Medical School and his PhD in genetics at Harvard University in six years. He majored in economics, literature, and biology while completing a BA summa cum laude and Phi Beta Kappa at Columbia University in three years. After graduating from Columbia, and prior to graduate schools, Christoph spent one year working with a medical team and studying in Cameroon and at the Albert Schweitzer Hospital in Africa, and worked for one year at a Max Planck Institute in Germany as a Fulbright/DAAD scholar. |
 |
| James M. Garvey, CEO and Managing Partner, Schroder Ventures Life James joined Schroder Ventures Life Sciences (“SVLS”) in May 1995 as Chief Executive Officer and Managing General Partner of SVLS, overseeing its approximately $500m investment activity. James brings a successful healthcare investment track record, preceded by 18 years of operating management experience. Prior to joining SVLS, he was Managing Director for the $600m Venture Capital Division of Allstate Corporation preceded by managing Allstate’s health care investment activity. He has held several senior management positions in companies with multinational operations including Kendall (TyCo & Millipore). He was also president of start-ups Allegheny International Medical Technology and National Teledata. James has served on the boards of private and public companies in the US and Europe including public companies Arris Pharmaceuticals, LaserVision Centers, Orthovita, Shire Pharmaceuticals and SunRise Assisted Living. James received a BS degree from Northern Illinois University in 1969. |
 |
| Paul Sekhri, Partner, Healthcare Technology, The Sprout Group Paul Sekhri joined Sprout in December 2002 as a Partner for healthcare technology investments. Prior to joining Sprout, Paul was Senior Vice President and Head of Global Search and Evaluation, Business Development and Licensing for Novartis Pharma AG. At Novartis, he was responsible for the creation of Novartis Pharmaceuticals' disease area strategy, as well as establishing a dedicated function focused on the identification and evaluation of new opportunities for the company. Prior to this, Paul set up a new department, Early Commercial Development, in order to ensure the differential competitive advantage of Novartis' pipeline. In the 1990's, Paul held senior management positions at biotechnology firms, including Millipore Corporation, where he led the Applied Microbiology Strategic Business Unit, creating joint ventures with other biotechnology firms and strategic collaborations with several pharmaceutical companies. Previously, he held managerial positions in healthcare marketing at Zymark Corporation and Genex Corporation. Paul received his BS in molecular biology and completed his graduate work in Neuroscience at the University of Maryland School of Medicine. Contact Information: 212-538-3600, paul.sekhri@sproutgroup.com |
 |
| Dr. Gert A. Caspritz, General Partner, Techno Venture Management Dr. Gert A. Caspritz serves on the boards of directors of Altor, Inc., Coley Pharmaceutical Group, Inc., CyDex, Inc., Enanta Pharmaceuticals, Inc., EpiCept Corp., Pain Therapeutics, Inc., Precision Therapeutics, Inc., TissueInformatics.Inc, Transave, Inc., TransMolecular Pharmaceuticals, Inc. and VivoQuest Inc. Prior to joining TVM in June of 1999, he had an eighteen year career with Hoechst AG (now known as Aventis). Most recently he was Vice President of New Technologies Licensing at Hoechst Marion Roussel, the pharmaceutical company of Hoechst, where he bore worldwide primary responsibility for identifying business opportunities in the area of enabling technologies and early-stage product development in both industry and academia. He was also a member of various teams that dealt with the development of a strategy for HMR´s overall R&D, and specifically for oncology and bone diseases. Dr. Caspritz was previously Assistant to the Head of Hoechst's worldwide pharmaceutical research, and, prior to that, was Head of a CNS drug screening laboratory. He also established a laboratory for immunopharmacological drug screening, as well as an integrated drug screening group. He holds degrees in biology and microbiology from the University of Mainz, where he wrote his doctoral thesis. |
 |
| Stewart J. Hen, Managing Director, Warburg Pincus LLC Mr. Hen is a Managing Director at Warburg Pincus LLC based in New York. He focuses on life sciences investments including biotechnology, pharmaceuticals, specialty pharmaceuticals, drug delivery and diagnostics. Prior to joining Warburg Pincus, Mr. Hen was a management consultant at McKinsey & Company where he advised pharmaceutical and biotechnology companies on a range of strategic management issues. Prior to McKinsey, he worked at Merck & Company in both R&D and manufacturing. Mr. Hen holds an M.B.A. from The Wharton School where he was named a Palmer Scholar, an M.S. in chemical engineering from the Massachusetts Institute of Technology where he was an NSF Fellow, and a B.S. in chemical engineering from the University of Delaware. Mr. Hen is a director of The Medicines Company, Triangle Pharmaceuticals and Synaptic Pharmaceuticals. He also serves on the Health Care & Sciences Group of the New York City Investment Fund. |
 |
| Ben Bronstein, Managing Director, Zero Stage Capital Dr. Bronstein joined Zero Stage Capital in 1999. He has responsibility for life sciences investing and advises portfolio companies on organizational, research and development, and business development issues, working closely with them from start-up through more advanced stages of development. Recently, he served as interim CEO of Spherics, a Zero Stage Capital portfolio company developing bioadhesive oral drug delivery systems. Dr. Bronstein has more than a decade of experience as a biotech entrepreneur, corporate executive, and advisor to biomedical and scientific companies. He was co-founder, president, and chief executive officer of Peptimmune, Inc., a venture capital financed biotechnology company developing immunotherapeutics, which was acquired by Genzyme in July 1999. Prior to Peptimmune, he was a senior executive with Seaflower Associates, Inc., a private equity advisory firm in Waltham, MA. From 1989-1993 Dr. Bronstein served as vice president of medical affairs and medical director of BioSurface Technology, Inc., which was acquired by Genzyme Corporation after an initial public offering. Dr. Bronstein began his career as a staff pathologist at the Massachusetts General Hospital and was on the faculty of Harvard Medical School. In addition to serving as a director on the boards of privately held life sciences companies, Dr. Bronstein is board member of Rhode Island’s Slater Center for Biomedical Technology. Dr. Bronstein received an A.B. in biology (magna cum laude), an MD degree, and an MBA (with high honors) all from Boston University. |
 |